Perseus Proteomics Inc.(4882) News

Announcement of a Presentation at an International Symposium Regarding PPMX-T003

Non-consolidated Summary of Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026

Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses

Perseus Proteomics, Apr-Dec (Cumulative 3Q) Net Income Loss Narrows, Oct-Dec Net Income Loss Narrows

Announcement of Presentation at The 4th Annual Meeting of The Japanese Antibody Society

Notice of Joint Research Agreement with Eurus Therapeutics Inc. for the Utilization of PPMX Antibody Library

Presentation Material for FY2026/3 First Half Business Results

Non-consolidated Summary of Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026

Perseus Proteomics, First Half Net Income Loss Narrows, Jul-Sep Net Income Loss Narrows

Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses

Notice of Extension of Investigator-Initiated Phase I/II Clinical Trial Period for PPMX-T003 in Aggressive NK-Cell Leukemia (ANKL)

Notice Regarding Execution of Joint Research Agreement between PPMX and ASKA Pharmaceutical for Creation of Novel Antibody Drugs

Announcement of New Antibody and Reagent Product Launch

Announcement of Acceptance for Three Poster Presentations at the 4th Annual Meeting of the Japan Antibody Society

Notice of Selection for JST A-STEP Program－Industry-Academia Collaboration Stage II (Full-Scale Phase)

Perseus Proteomics, Apr-Jun (1Q) Ordinary Profit Loss Narrows

Notice on Recording of Non-operating Income, Non-operating Expenses, and Extraordinary Losses

Non-consolidated Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2026

Business Results Summary for Q1 FY2026/03

Notice of Acceptance for Presentation at the 84th Annual Meeting of the Japanese Cancer Association